Murakoshi T
Hokkaido Igaku Zasshi. 1982 May;57(3):351-63.
This study was made to know the significance of fibrinopeptide A(FPA) as an indicator for coagulative analysis in thrombotic diseases. In normal control subjects (n=21), values of FPA by the radioimmunoassay were 0.5 +/- 1.4 ng/ml (mean +/- SD). In animal models, using Lyoplastin (tissue thromboplastin, n=5) or Ancrod (n=5) to piglets, plasma FPA levels elevated rapidly as a reflection of fibrin formation, and these changes of FPA were found to be most rapid and sensitive among the indicators for coagulation and fibrinolysis. In patients with thrombosis (n=32), elevated FPA levels (14.7 +/- 13.8 ng/ml) and beta-thromboglobulin (beta-TG)(86.1 +/- 65.6 ng/ml) were found. FPA levels in these patients positively correlated to beta-TG (r=0.5539, P less than 0.05) and inversely to fibrinogen (fbg) (r= -0.3622, P less than 0.05). In patients with acute myelocytic leukemia (AML, n=112), acute promyelocytic leukemia (APL, n=18) and acute lymphocytic leukemia (ALL, n=15), mean FPA levels in patients with active signs and symptoms were significantly higher (AML: 13.5 ng/ml, APL: 20.8 ng/ml, ALL: 12.4 ng/ml) than those examined during remission states (AML: 7.7 ng/ml, P less than 0.02, APL: 3.9 ng/ml, P less than 0.01, ALL: 2.7 ng/ml, P less than 0.01). FPA levels in patients with APL inversely correlated to fbg (r= -0.6399, P less than 0.01). In patients with lung cancer (n=75), mean FPA level in advanced stage (17.7 ng/ml, n=67) were significantly higher than those examined in early stage 6.5 ng/ml, n=8, P less than 0.001). In patients with acute disseminated intravascular coagulation (n=12), prolonged prothrombin time and activated partial thromboplastin time, severely reduced fbg and platelets, and remarkably elevated fibrin degradation product were found. Elevated FPA and beta-TG levels were also found (FPA: 23.5 +/- 15.0 ng/ml, beta-TG: 100.0 +/- 63.0 ng/ml). In five patients with thrombotic diseases who were treated successfully with 12500 IU of heparin per 12 hours (subcutaneous injection), plasma FPA levels were reduced to near normal levels quicker than changes of other indicators. These clinical and experimental data suggested that FPA was an useful indicator for active coagulation process.
本研究旨在了解纤维蛋白肽A(FPA)作为血栓性疾病凝血分析指标的意义。在正常对照受试者(n = 21)中,放射免疫法检测的FPA值为0.5±1.4 ng/ml(平均值±标准差)。在动物模型中,给仔猪使用促凝血酶原激酶(组织凝血活酶,n = 5)或安克洛酶(n = 5),血浆FPA水平迅速升高,反映了纤维蛋白的形成,并且发现FPA的这些变化在凝血和纤溶指标中是最迅速和敏感的。在血栓形成患者(n = 32)中,发现FPA水平升高(14.7±13.8 ng/ml)和β-血小板球蛋白(β-TG)(86.1±65.6 ng/ml)升高。这些患者的FPA水平与β-TG呈正相关(r = 0.5539,P<0.05),与纤维蛋白原(fbg)呈负相关(r = -0.3622,P<0.05)。在急性髓细胞白血病(AML,n = 112)、急性早幼粒细胞白血病(APL,n = 18)和急性淋巴细胞白血病(ALL,n = 15)患者中,有活动体征和症状的患者的平均FPA水平(AML:13.5 ng/ml,APL:20.8 ng/ml,ALL:12.4 ng/ml)显著高于缓解期检测的水平(AML:7.7 ng/ml,P<0.02,APL:3.9 ng/ml,P<0.01,ALL:2.7 ng/ml,P<0.01)。APL患者的FPA水平与fbg呈负相关(r = -0.6399,P<0.01)。在肺癌患者(n = 75)中,晚期(17.7 ng/ml,n = 67)的平均FPA水平显著高于早期(6.5 ng/ml,n = 8)检测的水平(P<0.001)。在急性弥散性血管内凝血患者(n = 12)中,发现凝血酶原时间和活化部分凝血活酶时间延长,纤维蛋白原和血小板严重减少,纤维蛋白降解产物显著升高。还发现FPA和β-TG水平升高(FPA:23.5±15.0 ng/ml,β-TG:100.0±63.0 ng/ml)。在5例血栓性疾病患者中,每12小时皮下注射12500 IU肝素成功治疗后,血浆FPA水平比其他指标的变化更快降至接近正常水平。这些临床和实验数据表明,FPA是活性凝血过程的一个有用指标。